6651 related articles for article (PubMed ID: 21954736)
21. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
22. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
Nahabedian MY; Tufaro AP; Manson PN
Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
[TBL] [Abstract][Full Text] [Related]
23. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
24. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
[TBL] [Abstract][Full Text] [Related]
25. High serum galectin-3 in advanced melanoma: preliminary results.
Vereecken P; Zouaoui Boudjeltia K; Debray C; Awada A; Legssyer I; Sales F; Petein M; Vanhaeverbeek M; Ghanem G; Heenen M
Clin Exp Dermatol; 2006 Jan; 31(1):105-9. PubMed ID: 16309497
[TBL] [Abstract][Full Text] [Related]
26. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
27. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma.
Vuylsteke RJ; Borgstein PJ; van Leeuwen PA; Gietema HA; Molenkamp BG; Statius Muller MG; van Diest PJ; van der Sijp JR; Meijer S
Ann Surg Oncol; 2005 Jun; 12(6):440-8. PubMed ID: 15864481
[TBL] [Abstract][Full Text] [Related]
28. [Neuron-specific enolase (NSE)--a suitable tumor marker in malignant melanoma?].
Hornef S; Lux J; Rassner G
Hautarzt; 1992 Feb; 43(2):77-80. PubMed ID: 1347764
[TBL] [Abstract][Full Text] [Related]
29. Sentinel node identification by scintigraphic methods in cutaneous melanoma.
Dias Moreira R; Altino de Almeida S; Maliska Guimarães CM; Resende JF; Gutfilen B; Barbosa da Fonseca LM
J Exp Clin Cancer Res; 2005 Jun; 24(2):181-5. PubMed ID: 16110749
[TBL] [Abstract][Full Text] [Related]
30. Sentinel lymph node biopsy in patients with thin melanoma: occurrence of nodal metastases and its prognostic value.
Vermeeren L; Van der Ent F; Sastrowijoto P; Hulsewé K
Eur J Dermatol; 2010; 20(1):30-4. PubMed ID: 19889594
[TBL] [Abstract][Full Text] [Related]
31. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.
Page AJ; Carlson GW; Delman KA; Murray D; Hestley A; Cohen C
Am Surg; 2007 Jul; 73(7):674-8; discussion 678-9. PubMed ID: 17674939
[TBL] [Abstract][Full Text] [Related]
32. Sentinel lymph node biopsy in elderly irish patients with malignant melanoma.
Moran DE; Smith MJ; O'Sullivan MJ; Bannon H; Crotty TB; Collins CD; Skehan SJ; O'Higgins N; McDermott EW; Evoy D; Hill AD
Ir Med J; 2007 Apr; 100(4):422-4. PubMed ID: 17566474
[TBL] [Abstract][Full Text] [Related]
33. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
[TBL] [Abstract][Full Text] [Related]
34. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
35. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection.
Rutkowski P; Nowecki ZI; Zurawski Z; Dziewirski W; Nasierowska-Guttmejer A; Switaj T; Ruka W
Eur J Cancer; 2006 Jan; 42(2):159-64. PubMed ID: 16324835
[TBL] [Abstract][Full Text] [Related]
36. [The prognostic role of clinical factors, VEGF, IL-8 and sTNF-R1 in cutaneous melanomas at locoregional stage].
Ługowska I; Kowalska M; Zdzienicki M; Fuksiewicz M; Kamińska J; Szamotulska K; Rutkowski P
Pol Merkur Lekarski; 2012 Jan; 32(187):22-7. PubMed ID: 22400175
[TBL] [Abstract][Full Text] [Related]
37. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein.
Beyeler M; Waldispuhl S; Strobel K; Joller-Jemelka HI; Burg G; Dummer R
Dermatology; 2006; 213(3):187-91. PubMed ID: 17033166
[TBL] [Abstract][Full Text] [Related]
38. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
[TBL] [Abstract][Full Text] [Related]
39. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
40. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
